Ann: RELINT: FPH: Disclosure of Director & Senior Manager...

• Release Date: 02/03/16 16:15
• Summary: RELINT: FPH: Disclosure of Director & Senior Manager Relevant Interests
• Price Sensitive: No
• Download Document  8.49KB

					FPH
02/03/2016 16:15
RELINT
NOT PRICE SENSITIVE
REL: 1615 HRS Fisher & Paykel Healthcare Corporation Limited

RELINT: FPH: Disclosure of Director & Senior Manager Relevant Interests

To NZX Limited; and
  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  2-Mar-16
Date of last disclosure:   11-Dec-15

Director or senior manager giving disclosure
Full name(s):  Michael Grenfell DANIELL
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  "Managing Director/
Chief Executive Officer"

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "(a) Beneficial Interest in
Ordinary Shares
(b) Beneficial interest in options to acquire Ordinary Shares"
For that relevant interest-
Number held in class before (a) exercise; (b) acquisition:  "(a) 173,388
(b) 710,000 "
Number held in class after (a) exercise; (b) acquistion:  "(a) 232,165
(b) 630,000"
Current registered holder(s):  Michael Grenfell DANIELL
Registered holder(s) once transfers are registered:  Michael Grenfell DANIELL

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Details of transactions requiring disclosure-
Date of transaction:  29-Feb-16
Nature of transaction:  "Exercise of 80,000 Options to acquire Ordinary
Shares
"
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ535,797.38
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not applicable
Date of the prior written clearance (if any):  Not applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:  "(a) Ordinary Shares
(b) Performance Share Rights over Ordinary Shares"
For that relevant interest,-
Number held in class:  (a) 769,109 (b) 110,000
Current registered holder(s):  "(a) Daniell Family Trust - Trustee &
Beneficiary
(b) Michael Grenfell DANIELL"

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

To NZX Limited; and
Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  2-Mar-16
Date of last disclosure:   11-Dec-15

Director or senior manager giving disclosure
Full name(s):  ANTONY GEORGE BARCLAY
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "Beneficial interest in
Ordinary Shares
"
For that relevant interest-
Number held in class before acquisition or disposal:  "102,549
"
Number held in class after acquisition or disposal:  52,549
Current registered holder(s):  ANTONY GEORGE BARCLAY
Registered holder(s) once transfers are registered:  ANTONY GEORGE BARCLAY

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  26-Feb-16
Nature of transaction:  Sale of 50,000 Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ$454,900
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:  "(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
(c)  Shares in Trust under Employee Share Scheme
"
For that relevant interest,-
Number held in class:  "(a)279,500
(b) 56,500
(c) 410"
Current registered holder(s):

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
End CA:00278690 For:FPH    Type:RELINT     Time:2016-03-02 16:15:44